AtriCure Inc (NASDAQ:ATRC) reported financial results for the fourth quarter and full year of 2025 that delivered a significant earnings surprise, propelling its shares higher in after-hours trading. The medical device company, which specializes in surgical treatments for atrial fibrillation, posted quarterly revenue that narrowly missed analyst expectations but swung to a profit on an adjusted basis against forecasts for a loss.
Earnings and Revenue Versus Estimates
The company’s top-line performance for the quarter was slightly below the consensus view, while its bottom-line result was a clear beat.
- Q4 2025 Revenue: $140.5 million, compared to analyst estimates of approximately $142.6 million.
- Q4 2025 Adjusted EPS: $0.06, significantly above analyst estimates for a loss of $0.10 per share.
For the full year 2025, AtriCure reported revenue of $534.5 million, representing growth of nearly 15% over the prior year. The adjusted net loss for the year improved to $0.11 per share from $0.67 in 2024.
Market Reaction and Price Action
The market’s initial reaction was decisively positive, focusing on the profitability milestone. Following the earnings release, AtriCure’s stock rose approximately 9.2% in after-market trading. This surge suggests investors were encouraged by the company’s improved earnings trajectory and forward guidance, looking past the slight revenue miss. The positive after-hours move stands in contrast to the stock’s performance over the past month, during which it had declined roughly 15.6%.
Key Highlights from the 2025 Report
The earnings report highlighted several areas of strength and strategic progress:
- Broad-Based Growth: Revenue growth was driven by the company’s pain management, open ablation, and left atrial appendage management (LAAM) product lines. International revenue grew 20.2% for the full year.
- Improving Profitability: The company reported a quarterly profit from operations of $2.5 million, a substantial improvement from an operating loss of $14.5 million in the prior-year period. Full-year Adjusted EBITDA nearly doubled to $61.8 million.
- Strong Balance Sheet: AtriCure ended the year with $167.4 million in cash and cash equivalents, an increase of over $44 million from the end of 2024.
2026 Outlook Compared to Analyst Expectations
Management provided financial guidance for 2026 that appears ambitious relative to existing analyst forecasts.
- Revenue Guidance: AtriCure projects 2026 revenue of $600 million to $610 million, implying growth of 12% to 14%. This range is notably below the current analyst sales estimate of approximately $612.4 million for the full year.
- Profitability Guidance: The company forecasts full-year positive net income and adjusted EPS in the range of $0.09 to $0.15. This outlook for sustained profitability is a key development for the company.
- Q1 2026 Implied Guidance: While not providing explicit quarterly guidance, the full-year outlook suggests a first-quarter revenue run-rate that would need to accelerate to meet the annual target, given the current Q1 analyst sales estimate of $141.9 million.
The company attributed its performance to strong execution and momentum across its business, with CEO Michael Carrel citing advancements in key clinical trials as positioning AtriCure for "sustained value creation."
For a detailed breakdown of future earnings estimates and historical performance, you can review the full data on AtriCure’s earnings and estimates page.
Disclaimer: This article is for informational purposes only and does not constitute investment advice, financial analysis, or a recommendation to buy or sell any security. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions.